The next generation biopharmaceuticals
Affibody Completes Enrollment in Phase 2 Psoriasis Trial of ABY-035
Solna, Sweden, February 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of enrollment in the Company’s Phase 2 proof-of-concept study of ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).
“We are pleased that the Phase 2 AFFIRM-35 study with ABY-035 is now fully recruited. This study has been designed using the accumulated knowledge of the IL-17 field to fully explore the unique opportunity that ABY-035 represents. We look forward to the trial results and hope that ABY-035 will become a new treatment paradigm of choice for psoriasis and psoriatic arthritis patients”, said David Bejker, CEO of Affibody. “Now with approximately 300 subjects dosed, Affibody has completed the transition from a technology platform company to a clinical stage, drug development company with a broad pipeline.”
The double-blind, placebo controlled, Phase 2 proof-of-concept study (AFFIRM-35, NCT03591887) enrolled 100 moderate-to-severe psoriasis patients in centers throughout Germany to evaluate the efficacy, safety and tolerability of ABY-035. The primary efficacy measure is PASI 90 at twelve weeks. Secondary endpoints include absolute and relative PASI-measures at weeks 12, 24, and 52; DLQI; itch and pain VAS; safety and tolerability, and pharmacokinetics.
Affibody is a clinical stage Swedish biotech company with a broad product pipeline focused on developing innovative next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
The company operates a focused experimental medicine model and currently has three clinical stage proprietary programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q2 (August 23, 2018)